In June, the U.S. Court of Appeals for the Federal Circuit issued ten written opinions pertaining to the Patent Trial and Appeal Board (PTAB) and district court proceedings. Among these, five cases stand out due to their potential implications for future patent litigation strategies and procedural conduct in hearings. The reversals and vacated decisions offer critical insights, particularly for branded drugmakers considering litigation against generic-drug manufacturers for off-label uses.
The highlighted cases emphasize the risks associated with violating pretrial orders and offering testimony that might not be in compliance with procedural directives. Legal professionals should take note of the potential repercussions of such actions, which may lead to reversals or modifications of decisions previously in their favor. For a detailed analysis and further case-specific information, Denise De Mory and Li Guo at Bunsow De Mory offer their expert perspective on the [Law360](https://www.law360.com/articles/1863430/patent-lessons-from-5-federal-circuit-reversals-in-june) website.